MOLN:NASDAQMolecular Partners AG Analysis
Data as of 2026-05-19 - not real-time
Latest Price
Risk Level: Medium
Executive Summary
Molecular Partners (MOLN) trades at $3.80, barely above its calculated support of $3.71, while the 20‑day SMA ($4.19) sits just above price, hinting at short‑term pressure. The RSI of 34 signals oversold conditions and the MACD is in a bearish divergence, suggesting a possible bounce but still a cautious outlook. Volatility is elevated at ~48% over the past 30 days, yet beta is only 0.18, indicating the stock moves largely independently of the broader market. Analysts are overwhelmingly bullish (strong‑buy) with a median price target near $12, implying a >190% upside. The catalyst landscape is positive: recent conference presentations and new pre‑clinical data on the lead Radio‑DARPin MP0712 and the Switch‑DARPin MP0632 could de‑risk the pipeline and drive momentum.
Market Outlook
Short Term
< 1 yearKey Factors
- Price near technical support with oversold RSI
- Increasing volume indicating renewed buying interest
- Upcoming early clinical read‑outs for MP0712
Medium Term
1–3 yearsKey Factors
- Strong analyst consensus and >190% upside potential
- Progression of multiple DARPin candidates through Phase 1/2
- Robust cash position relative to modest debt
Long Term
> 3 yearsKey Factors
- Unique DARPin platform offering differentiated oncology therapies
- Potential for partnership or out‑licensing revenue streams
- Long‑term valuation upside supported by pipeline milestones
Key Metrics & Analysis
Financial Health
Technical Analysis
Valuation
Risk Assessment
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.